Actinogen Medical

Overview
Price performance
Financials
Research
Thematics

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb portion of the XanaMIA trial will be key for validating the encouraging Xanamem data shown to date.

Latest Insights

Healthcare |
Flash note

27.08.24

Actinogen Medical — Further positive XanaCIDD results on depression

Healthcare |
Update

22.08.24

Actinogen Medical — XanaCIDD data narrow the focus in depression

Healthcare |
Flash note

28.06.24

Actinogen Medical — Publication of XanADu biomarker analysis

Healthcare |
Update

15.05.24

Actinogen Medical — Funding in place through key catalysts

Visit Website

Sector

Healthcare

Equity Analyst

Pooya Hemami

Analyst - Healthcare

Soo Romanoff

Managing Director - Head of Content, Healthcare

Arron Aatkar

Associate analyst

Jyoti Prakash

Analyst, Healthcare

Key Management

Dr Steven Gourlay

CEO and MD
Michael Roberts

Head of investor relations

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	16.1	9.1	65.9
Relative	12.4	4.7	48.1
52 week high/low	A$0.1/A$0.0

Financials

Actinogen Medical’s lead asset, Xanamem, is a once-daily oral selective 11beta-HSD1 inhibitor, designed to cross the blood-brain barrier and target excess brain cortisol, which has been associated with cognitive impairment (CI) in chronic brain conditions such as Alzheimer’s disease (AD), the company’s lead indication. Positive results in healthy adults demonstrated the drug’s initial efficacy, while an analysis of biomarker-positive (pTau-181) patients using plasma samples from the previous XanADu study in mild AD also showed clinical activity using the CDR-SB scale. Actinogen dosed the first patient in its Phase IIb XanaMIA trial in patients with biomarker-confirmed early AD in Q224, and plans to report interim data in mid CY25. Actinogen is also evaluating Xanamem as a treatment for depression symptoms in major depressive disorder (MDD), following positive efficacy signals shown in the Phase IIa XanaCIDD study.